98
Views
17
CrossRef citations to date
0
Altmetric
Original Article

Cystatin C as a filtration marker – haemodialysis patients expose its strengths and limitations

, &
Pages 65-72 | Received 10 Apr 2008, Accepted 23 Jun 2008, Published online: 08 Jul 2009
 

Abstract

Objective. The reliability of serum cystatin C (s‐Cys) as a filtration marker depends on the intra‐ and inter‐individual variation and influence of non‐renal factors of its production rate (Cyspr), non‐renal clearance (CLnr) and sieving coefficient (S). Haemodialysis patients with no residual renal function would be the best population in which to investigate these variables, which otherwise require reliable GFR measurements. Material and methods. Seventy‐nine haemodialysis (HD) patients with negligible residual renal function (Group 1) were investigated and compared with 55 HD patients with varying degrees of residual renal function (Group 2) and 923 non‐dialysis patients (Group 3). The equation eGFR = Cyspr/s‐Cys−CLnr was used to analyse the turnover and variation of cystatin C. Results. A formula for estimating GFR, eGFR = 99/s‐Cys−14.1, calculated from Group 3, was shown to fit the HD patients. The measured s‐Cys in Group 1 was 6.9±0.9 and 6.4±1.1 mg/L in Group 2. The calculated 95 % confidence interval of eGFR of ±(30–40) % increased sharply below GFR 20 mL/min/1.73 m2, which means that s‐Cys cannot be used for calculating low GFR, including the residual GFR of dialysis patients. Conclusions. Nicotine users in Group 1 had significantly higher s‐Cys than non‐users (7.5±0.9 mg/L compared to 6.7±0.8; p = 0.0008), which may be a factor to include in the eGFR formulae. However, s‐Cys was independent of non‐renal factors such as sex, age, LBM, body weight, malnutrition and CRP and also of changes in CRP.

Acknowledgements

We thank the dialysis departments in Eskilstuna, Falun, Gävle, Karlskoga, Karlstad and Mora for contributing serum samples. We also thank Gunilla Karlsson, Else‐Mari Hernbrand and Annika Löwenhamn for excellent technical assistance.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.